Our innovative trauma and analgesia care portfolio includes morphine autoinjector, and upcoming pipeline products like TXA autoinjector and ketamine autoinjector.
Designed to help alleviate trauma-induced pain in combat situations and provide immediate pain relief without the need for administration through IV access.
Supplied to the Israeli army (IDF) and NATO member states under Emergency Use Authorizations.
*Morphine is a scheduled/controlled substance with a potential for abuse or dependency.
TXA is an anti-fibrinolytic agent that stabilizes blood clots and helps prevent excessive blood loss.
Growing evidence point to the importance of timely management of bleeding trauma patients (e.g., battlefield injuries, mass casualty shooting events).
Rafa is revolutionizing the administration of tranexamic acid (TXA) with the development of a concentrated formulation to be integrated in autoinjectors and pre-filled syringes for intramuscular administration. This development will empower first responders and military medics to rapidly treat large numbers of casualties in parallel, in emergencies such as terror attacks.
In addition to the autoinjector and PFS, Rafa is committed to making a positive impact by creating an affordable, reliable, and user-friendly TXA solution presentation in ampules for intramuscular injection. This advancement could facilitate accessible treatment for postpartum hemorrhage (PPH) in rural and remote regions of low-middle-income countries, eliminating the need for intravenous administration.
Ketamine is a dissociative anesthetic used medically for induction and maintenance of anesthesia. Moreover, it serves as a tool for pain management.
Rafa's efforts include the development of a ketamine autoinjector, aimed at providing rapid pain relief in combat trauma situations. Ketamine autoinjector may be useful in reducing the amount of opioids required to provide effective pain relief.
* Ketamine is a scheduled/controlled substance with a potential for abuse or dependency.
